Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I second that emotion!
With what the company has in it's pipeline and existing and new trials lined up, I think it should at LEAST be at $20 now. The market sees it differently at the moment but I hope they share my view soon.
Blackrock appears to be the biggest buyer in May on 5/12 (as far as I can see).
https://fintel.io/so/us/adxs
"Aratana has completed enrollment of a pivotal field safety study related to AT-104, their proposed treatment for canine osteosarcoma. They anticipate conditional licensure by the United States Department of Agriculture-USDA, in the second half of 2017."
From a recent SA article.
https://seekingalpha.com/article/4080942-aratana-might-want-grab-shares-rapidly-expanding-companion-animal-market?v=1497331340&comments=show
I know James S talked to the company and they said the combo trial was still ongoing. Anybody else talk to IR abut this?
Bourbon, I've felt the same way for some time. That would be a great question to raise at the presentation today. The "new" FDA seems to be more generous with approvals. Merck is racking them up.
Umm...so what changed in 3 days?
"$10 soon ;) ADXS"
"...Amgen had their pick of the litter..." and they chose us. Anyone doubt Amgen's litter picking abilities?
I did mean the current PIII. Sorry for the confusion. Watching the Comey testimony and trying to respond to a post at the same time. I should have clearer.
And I believe a lot of the cost is already covered.
1,000,000+ shares traded so far.
"For leiomyosarcoma and liposarcoma, ORR was 10% vs 4% for SOC (P = 0.079) Overall survival was, however, similar: 12.88 vs 12.16 months for SOC." Over double the ORR compared to SOC for these indications. That makes it a winner to me.
And there's still the 2nd line SCLC trial results to be reported.
That would suit me just fine, Attila. I see we're both in a few of the same stocks. Here's hoping they ALL get buyouts!
"...we really believe that there is a strong potential for an accelerated approval in this nonresponder patient population, of course based on the clinical trials outcome."
This was the best part of the call for me. The "new" FDA seems to really be interested in cutting approval time from what I can tell.
I don't recall AT-014 being so prominent in previous Aratana presentations...around slides 28/29
https://seekingalpha.com/article/4078122-aratana-therapeutics-petx-presents-stifel-2017-dental-and-veterinary-conference-slideshow
Let's hope that what helped him will soon be helping many others to beat the odds. We should know soon enough.
Anyone planning to attend the Investor Day? Wish I could but distance prevents it at this time.
Um...Amgen paid $40Mil up front. The AXAL GOG Study 0265 had 12 month overall survival of 38% which beat the historical 30%. The Phase 1/2 Brown study in high risk advanced anal cancer had all patients who completed RT and received treatment achieve a CR at
six months. The historical 3 year recurrence rate is around 45%. By the chart included in the corporate presentation 5 of the 9 appear to have already exceeded that timeframe. If AXAL didn't work, how do you explain the results? You may wish to do at least some cursory DD before making such allegations.
I have a positive interpretation of the collaboration. ADXS-DUAL is a new construct with added target antigens. Perhaps Astra did not want to start another trial until they see proof positive that the current ones are effective. Meanwhile, BMS comes on board to try their luck and test the efficacy of Opdivo with AXAL. After the lung cancer trail failure, I'm sure BMS wants a winner. I would love to see the price jump up on the news but we know how this stock reacts to PRs. Still have hopes for an EU deal soon.
I really like your way of thinking. It would not surprise me if the company had the same thoughts.
Could be partially attributed to an analyst cutting price target but kept outperform rating.
https://www.smarteranalyst.com/2017/05/26/rexahn-pharmaceuticals-inc-rnn-challenged-financing-overhang-fbr-slashed-price-target/
Sort by file date to see who's buying and selling for the month.
https://fintel.io/so/us/adxs
And, of course, you can share any info on where the rumors originated. Thanks in advance.
Excellent point, fbg.
"Progress Towards Regulatory Submission and Commercial Readiness". This is the part I'm most interested in hearing about on June, 12. I assume we may get an enrollment update on the PIII, also.
Wishing you the best!
With this stock, it is so hard to tell. A great deal, a PETX approval or excellent results will move it upwards. Until then who knows. I have NO doubt the secret sauce works. Others just have to come to the table.
So, what is YOUR call for tomorrow?
Yes, they are.
There seems to be a rush to get a lot done in a little time. I would hope they wouldn't hire all these new people if they didn't have something concrete brewing shortly in the future.
Hopefully, he'll share what they say with us.
New job opening
Associate, Manufacturing
Overview:
The Manufacturing Associate will perform various biological manufacturing unit operations which includes aseptic cleaning, media/buffer preparation, fermentation, clarification and purification in a cGMP clinical manufacturing facility. Initial job responsibilities will include working with a group of manufacturing personnel responsible for a diverse range of manufacturing related activities during plant start-up from Operational Commissioning/Shakedown through process validation.
fbg
I believe you are right on the money here. I have felt the same way for a long while.
I wouldn't call over 200,000 shares traded (at the moment) no volume. I think volume may be picking up this week, also.
Approval of pembrolizumab, perhaps. Hopefully, will make our combo trial more efficacious.
They possibly did some pre-clinical work and found it worked well with Axalimogene. They're using it for the prostate trial and may have seen evidence that it could work in other trials as well.
I have little doubt it can be used with a variety of checkpoint inhibitors. That opens up multiple opportunities.
Absolutely!
With the best ever results for cervical cancer, I wondered why Advaxis did not go for (maybe they did) accelerated approval. The ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer trial would be a good one to go for, also.